We previously identified structurally diverse small molecule (non-peptidic) inhibitors (SMNPIs) of the botulinum neurotoxin serotype A (BoNT/A) light chain (LC). Of these, several (including antimalarial drugs) contained a 4-amino-7-chloroquinoline (ACQ) substructure and a separate positive ionizable amine component. The same antimalarials have also been found to interfere with BoNT/A translocation into neurons, via pH elevation of the toxin-mediated endosome. Thus, this structural class of small molecules may serve as dualfunction BoNT/A inhibitors. In this study, we used a refined pharmacophore for BoNT/A LC inhibition to identify four new, potent inhibitors of this structural class (IC 50 's ranged from 3.2 to 17 µM). Molecular docking indicated that the binding modes for the new SMNPIs are consistent with those of other inhibitors that we have identified, further supporting our structure-based pharmacophore. Finally, structural motifs of the new SMNPIs, as well as two structure-based derivatives, were examined for activity, providing valuable information about pharmacophore component contributions to inhibition.
Introduction
Botulinum neurotoxins (BoNTs) a are the most potent of the biological toxins; the lethal dose of BoNT serotype A (BoNT/ A) is estimated to be between 1 and 5 ng kg -1 for humans. 1, 2 As a result, these enzymes, which are responsible for the paralysis associated with botulism, are listed as category A (highest priority) biothreat agents by the Centers for Disease Control and Prevention (CDC). BoNTs are easily produced and may be delivered via food "spiking" and/or aerosol route. [2] [3] [4] [5] [6] Furthermore, as BoNTs are now used to treat a range of medical conditions, and in many cosmetic applications, 3, [7] [8] [9] [10] [11] [12] [13] [14] they are being produced in increasing quantities, making their misuse, accidental overdosing, and/or instances of adverse side effects 15 more likely. Neither the currently available CDC BoNT equine antitoxins, which can cause adverse anaphylaxis and serum sickness, 16 nor experimental antibodies can counter these enzymes once they are inside neurons. Furthermore, BoNT intoxication can occur rapidly, 17 and individuals who have been maliciously exposed to a BoNT(s), or have received an accidental overdose, will most likely seek medical attention only after clinical symptoms (i.e., muscle paralysis) manifest. At this time, critical care mechanical ventilation is the only life-saving option once diaphragm muscles cease to function. Yet, the effects of internalized BoNTs can last for weeks, 18, 19 rendering such medical care impractical for wide scale application. By comparison, small molecule (non-peptidic) inhibitors (SMNPIs) could serve as post-intoxication "rescue" therapeutics and prophylactics.
There are seven known BoNT serotypes (identified as A-F). Each cleaves a component of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex, 20, 21 which facilitates the transport of acetylcholine into neuromuscular junctions. BoNT serotypes A and E cleave SNAP-25 (synaptosomal-associated protein (25 kDa)), 22 serotypes B, D, F, 23 and G cleave VAMP (vesicle-associated membrane protein), [24] [25] [26] [27] and serotype C1 cleaves both SNAP-25 and syntaxin 1. 28 X-ray crystal structures of BoNT holotoxins 29, 30 show that these enzymes are composed of a heavy chain (HC) and a light chain (LC), which, following post-translational modification, are connected by a disulfide bridge. 29 The LC is a zinc metalloprotease. The HC transports the LC into the neuronal cytosol via an acidic endosome.
In a previous publication, 31 we identified a range of novel, structurally diverse, non-zinc chelating SMNPIs of the BoNT/A LC. In particular, we showed that several compounds containing the weakly basic (pK a ≈ 8) ACQ substructure and a separate ionizable amine component were among the most potent of the inhibitors. 31 Additionally, we proposed binding modes for the compounds and developed a common pharmacophore for BoNT/A LC inhibition. 31 In a subsequent molecular dynamics study, we demonstrated that conformationally flexible loops surrounding the BoNT/A LC substrate binding cleft may reorient to decrease the solvent accessibility of the cleft (as compared to respective energy refined structures), while simultaneously providing more hydropathically feasible binding contacts for SMNPIs. 32 The molecular dynamics studies were pivotal for identifying a binding mode 33 for the potent pseudo-peptide inhibitor 2-mercapto-3-phenylpropionyl-RATKML (mpp-RAT-KML, K i ) 330 nM 34 ). In the same study, we also proposed new pharmacophore components and constraints based on the docked model of mpp-RATKML, and, using this information, we identified more potent SMNPIs. 33 In this study, we build on our previous work by describing how the refined pharmacophore 33 was used to discover new small molecule inhibitors possessing the ACQ substructure and a separate ionizable, aliphatic amine component.
Results and Discussion
Based on the identification of N,N-bis(7-chloroquinolin-4-yl)diamines and five antimalarial drugs (amodiaquine, chloroquine, quinacrine, quinidine, and quinine) as SMNPIs of the BoNT/A LC, 31 we have continued to pursue the identification of new inhibitors of this structural class possessing the weakly basic ACQ substructure and an ionizable amine; both of these components have been found to be key to activity. 31 Further supporting this approach are the findings of Deshpande et al. 35 and Sheridan et al., 36 demonstrating that ACQ-based drugs, which also possess a separate ionizable nitrogen atom (e.g., amodiaquine), delay BoNT/A induced muscle paralysis. In those studies, it was hypothesized that the compounds act by interfering with toxin translocation, most likely by increasing the pH of the toxin-mediated endosome. 35, 36 This is a logical supposition as ACQ antimalarials have been shown to target and increase the pH of the acidic food vacuole of Plasmodium falciparum. [37] [38] [39] However, neither of the earlier studies reported LC inhibition in vitro. As indicated above, we demonstrated that several of the same antimalarials also directly inhibit BoNT/A LC metalloprotease activity; 31 however, they do so at higher concentrations than reported in the muscle twitch assays used in the earlier studies. 35, 36 This comparison indicates that the observed muscle twitch inhibition could not have resulted solely from inhibition of the enzyme's LC. Thus, the Deshpande et al. 35 and Sheridan et al. 36 data, in combination with our previous findings, indicate that such molecules may serve as dual-function countermeasures, acting both as translocation inhibitors and directly against the metalloprotease activity of the LC.
A Refined Pharmacophore Is Used To Identify New BoNT/A LC Inhibitors Possessing Both the ACQ Substructure and a Separate Ionizable Amine. The first step in identifying new SMNPIs was to use a recently refined/expanded pharmacophore for BoNT/A LC inhibition 33 ( Figure 1A ) to evaluate diverse target compounds possessing the ACQ substructure. It is important to note that the eight-component pharmacophore model presented in Figure 1A is a logical extension of the six-component model shown in our original work 31 and is part of an ongoing refinement of our pharmacophore for BoNT/A LC inhibition 32, 33 (which is occurring as more data become available). In this study, we wanted to identify compounds containing as many pharmacophore features as possible, but with the following specific components: (1) the ACQ substructure (which incorporates pharmacophore components A, a heteroatom associated with A, and C ( Figure 1A) ), (2) an ionizable amine located 6.5-9.5 Å from the centroid of the ACQ (pharmacophore component E ( Figure 1A) ), and (3) at least one of the new components from our expanded pharmacophore, either F 33 (a positive ionizable moiety located 11.7-16.7 Å from the quinoline centroid) or G 33 (a hydrophobic moiety located 8.5-12.5 Å from the quinoline centroid) ( Figure  1A ). Subsequently, a congeneric series of 4-amino-7-chloroquinoline-cholate-acetates, 1-3, and a tri-ACQ derivative, 4, were identified (see Scheme 1 for two-dimensional (2-D) structures of 1-3 and Figure 2 for the 2-D structure of 4).
Pharmacophore mapping to 1-4 indicated that in each case ACQ is plane A (Figure 1B-E) , and the quinoline ring nitrogen is the heteroatom associated with this plane. For 1-3, component B is the central decahydronapthalene of the methyl cholate acetate (rings B and C according to steroid ring designation) ( Figure 1B-D) , while in 4 it is a second ACQ ( Figure 1E ). Hydrophobic component C is the 7-chloro substituent of the plane A ACQ for all inhibitors ( Figure 1B-E) , and pharmacophore component D is a methyl for 1 ( Figure 1B) , an acetyl group for 2 and 3 ( Figure 1C and D) , and a chloro substituent for 4 ( Figure 1E ).
As a second specific criterion, each of the molecules contains a separate ionizable, aliphatic amine ( Figure 1B-E) , which corresponds to pharmacophore component E ( Figure 1A) . Finally, all of the molecules possess hydrophobic pharmacophore component G from the expanded/refined pharmacophore 33 ( Figure 1A ) (the third specified criterion, see above), which is an acetyl group for 1 and 2 ( Figure 1B and C) , a methyl group for 3 ( Figure 1D ), and a chloro substituent for 4 ( Figure 1E ). As observed in Figure 1B -E, 1-4 all show a good fit with respect to the distance constraints specified by the pharmacophore.
In Vitro Testing. Compounds 1-3 were initially examined for percent inhibition of the BoNT/A LC at 50 µM concentrations, while 4 was tested at a 20 µM concentration. Results from these initial analyses indicated 90% enzyme inhibition by 1 and (Table 1 ). In agreement with structurally distinct SMNPIs reported by our research group (possessing K i values ranging from 3.0 to 10.0 µM 33 ), compounds 1-4 demonstrate that our strategy of incorporating new pharmacophore features (i.e., pharmacophore components F or G), 33 in addition to original components, 31, 32 results in the identification of more potent inhibitors.
Molecular Docking of SMNPIs 1-4 Demonstrates a Consistency with Previous Inhibitor Binding
Modes, Reinforcing Our Structure-Based Pharmacophore Approach. Compounds 1-4 were docked in the BoNT/A LC substrate binding cleft to determine if they would also engage in intermolecular contacts that were comparable to those predicted for other structurally diverse SMNPIs. [31] [32] [33] Similar to our previously docked models of ACQ inhibitors, 31,32 the 7-chloro substituents of 1-3 ( Figure 3A -C) and one of the ACQs of 4 ( Figure 4A and B) engage in favorable hydrophobic contacts with residues Phe 162, Phe 163, and Thr 219 of hydrophobic binding subsite 1 [31] [32] [33] (also described as the S1′ binding site 34 ). At the same time, the quinoline nitrogens of the inhibitors are positioned so that this heteroatom may interfere with the enzyme's catalytic engine. This same heteroatom:catalytic engine perturbation has been a consistent theme in the docked models of described SMNPIs, including those in which pharmacophore plane A is an indolyl/benzofuranyl, [31] [32] [33] as well as those possessing the ACQ substructure. 31 Linker methylenes of 1-4 engage in favorable hydrophobic collapse with the side chain methylenes of Lys 65, and the hydrophobic side chains of Val 67 and Pro 68 (Figure 3A-C; Figure 4A and B). These residues are part of a flexible loop (LC residues 48-78, referred to as loop 1 for the remainder of the text) that reorients toward the enzyme's substrate binding cleft during molecular dynamics analysis. 32, 33 As in our previous reports, 32, 33 this loop reorientation, in addition to providing favorable new inhibitor contacts, also provides solvent shielding for SMNPIs. This is clearly observed in Figure 3A -C and Figure 4A and B, as loop 1 residues are located directly above atoms linking the ACQ and cholate-acetate components of 1-3, and two of the ACQs of 4.
The secondary nitrogens of 1-3, and the tertiary nitrogen of 4, engage in hydrogen bonds with the side chain carboxylate of Glu 63, a residue located in a polar contact region of the substrate binding cleft (Figure 3A -C; Figure 4A and B). [31] [32] [33] This intermolecular hydrogen bond is also consistent with our docked model of mpp-RATKML, 33 in which the Arg side chain guanidinium is predicted to engage in a hydrogen bond with the Glu 163 side chain carboxylate.
The steroidal components of 1-3, in addition to occupying a significant volume of the LC substrate cleft, also serve as rigid platforms for positioning key pharmacophore components in binding subsite 2. [31] [32] [33] For SMNPI 1, the C20 methyl group occupies steric space in the substrate cleft that is located directly behind His 226 and adjacent to Cys 164 ( Figure 3A ). For inhibitors 2 and 3, this same space is occupied by 7R-acetyl ( Figure 3B ) and 12R-acetyl ( Figure 3C ) substituents, respectively, while a second chloro substituent from SMNPI 4 occupies this space ( Figure 4A and B) . In each case, the binding modes of the methyl, acetyl, and chloro substituents are consistent with similar cleft occupancy observed for hydrophobic chloro, methyl, and methoxy substituents in the docked models of other, structurally diverse, SMNPIs. [31] [32] [33] The 7R-and 12R-acetyl substituents of SMNPIs 1 and 2, respectively, pack behind Pro 238 ( Figure 3A and B) , while the same steric space is occupied by the C13 methyl group of 3 ( Figure 3C ), and a third ACQ of SMNPI 4 ( Figure 4A and B). Moreover, two potential binding modes were identified for SMNPI 4. Specifically, we found that intramolecular π stacking between two of the three ACQ quinoline rings reinforces the stability of the predicted binding modes by significantly decreasing the conformational freedom of the inhibitor. In the first binding mode (Figure 4A ), hydrophobic packing near Pro 238 is achieved with the ACQ chloro substituent oriented into the substrate cleft, while in the second binding mode ( Figure  4B ) it is achieved with the chloro substituent facing the opposite direction.
For SMNPIs 1-4, favorable hydrophobic interactions with the Pro 238 side chain are consistent with those observed for the Met residue of the docked model of mpp-RATKML. 33 Indeed, the hydrophobic contacts between the mpp-RATKML Met and the side chain of Pro 238 were used to derive component G of the refined/expanded pharmacophore ( Figure  1A) . 33 Of significance to this study is the observation that the predicted binding modes of 1-4 indicate that the G component adds an additional hydrophobic anchor and, in doing so, results in improved substrate cleft complementarity.
Inhibitors 1-3 also resemble the docked model of mpp-RATKML in that the 3R-acetyl substituent of 1 and the C23 substituents of both 2 and 3 all dock so that a methyl moiety points toward and engages in favorable contacts with the side chain of Val 171, which is located in flexible loop 2 (residues 167-180) at the lower edge of the binding cleft (with respect to the orientation of the enzyme in Figure 3A -C). However, it is important to note that, while pharmacophore components of the SMNPIs share similar binding site contacts with corresponding components of mpp-RATKML, the unique, optimized steric occupancy achieved by the pseudo-peptide, 34 as compared to the identified SMNPIs, is reflected in the fact that it is still the most potent inhibitor of the BoNT/A LC reported to date. 33 Unfortunately, our ability to completely take advantage of this novel steric space is limited. This is due to a lack of steric congruency between the way in which the optimized pseudopeptide inhibitor 34 populates the BoNT/A LC substrate binding cleft and the positions on the SMNPIs where substituents can be added or modified.
Finally, inhibitor 4 also occupies additional steric volume in the substrate binding cleft (as compared to previously identified SMNPIs 31 ); in both of its proposed binding modes ( Figure 4A and B), one of the inhibitor's ACQ's packs behind His 169 (which is a residue of loop 2 that sits adjacent to Val 171 in the three-dimensional structure of the enzyme).
The Effects of Inhibitor Structural Motifs and Derivatives on BoNT/A LC Metalloprotease Activity: Pharmacophore Component E Dominates Potency for This Structural Class. The final analyses of this study involved determining the importance of the structural components of 1-4 to BoNT/A LC inhibition. To start, ACQ (4-amino-7-chloroquinoline, 5, Figure 2 ), the smallest substructure common to the SMNPIs, possessing pharmacophore component A, a heteroatom associated with this plane, and component C ( Figure 1A) , was evaluated. The rationale for examining 5 was to determine if two or more ACQs might simultaneously bind in the substrate cleft, similar to the docked model of inhibitor 4 (but without the need for a central linker). However, examination of this substructure in our assay resulted in only 12% inhibition at a concentration of 50 µM (Table 2) . Hence, while ACQ is a key component of molecules in this inhibitor class, it must be coupled with additional pharmacophoric features to achieve appreciable potency.
The above results prompted a question: would incorporating atoms of the flexible linkers of 1-4, along with pharmacophore component E, increase the potency of ACQ? Again, the smallest structural denominators of the inhibitors were examined. For 1-3, the substructure was N 1 -(7-chloroquinolin-4-yl)-ethane-1,2-diamine (6, Figure 2) , which was found to inhibit the BoNT/A LC by 33% at 50 µM concentration (Table 2) ; for 4, the substructure was N 1 -(7-chloroquinolin-4-yl)-propane-1,3-diamine (7, Figure 2) , which inhibited the enzyme by 22% at 50 µM concentration ( Table 2 ). On the basis of our docked models, we hypothesize that the increase in activity for 6 and 7 (over that of 5) results from a hydrogen bond with an acidic residue in the polar contact region (presumably Glu 63). Moreover, our models also predict that the side chain methylenes of 6 and 7 may desolvate under hydrophobic residues of loop 1, with the slightly lower potency of 7 most likely resulting from a higher entropic binding penalty.
Focus was next placed on the methyl cholate acetate component (8, Figure 2 ) of SMNPIs 1-3, which incorporates pharmacophoric features B, C, and G ( Figure 1B-D) . Because of its rigidity and bulk, it was hypothesized that 8 alone might demonstrate a moderate degree of inhibition; however, when examined at a 50 µM concentration against the BoNT/A LC, it was inactive (Table 2) . Thus, the steroidal motif alone cannot effectively populate the enzyme's substrate binding cleft in the absence of the ACQ and/or ionizable amine moieties. To determine if incorporating pharmacophore component E might transform 8 into an inhibitor, the 3R-acetyloxy group of this molecule was replaced with an ionizable 3R-NH 2 substituent (9, Figure 2 ), effectively creating a substructure of SMNPI 3 (Scheme 1), the most potent molecule of the ACQ-cholate acetate congener series ( Table 1) . Examination of 9 in the in vitro assay revealed that this was the case, as this substructure provided 13% enzyme inhibition at a 50 µM concentration (Table 2 ). These data both underscore the importance of an ionizable, aliphatic amine to the potency of this class of inhibitors, as well as the need for the ACQ component.
To further probe the requirements of pharmacophore component E, a new derivative of SMNPI 3 (Scheme 1) possessing a non-ionizable oxygen atom at the 3R position of the cholateacetate was generated. Designated 10 (Scheme 1), this molecule was designed to determine if an ether oxygen might also suffice at this key position. For example, it was hypothesized that a water molecule might bridge a hydrogen bond between the Glu 63 side chain carboxylate and the ether oxygen of 10. Interestingly, examination of 10 at 50 µM concentration resulted in only 9% enzyme inhibition (Table 2) , providing additional evidence that the ionizable, aliphatic amine found in SMNPIs 1-4 is interacting with an unprotonated acidic residue, as predicted by our molecular models (Figures 3 and 4) .
Finally, to determine if it would be possible to restore the inhibitory potency of 10, the 3R-O-cholate-acetate and ACQ components were tethered with an extended linker incorporating a central, secondary amine. Gratifying, the resulting derivative, 11 (Scheme 1), was found to inhibit the BoNT/A LC by 62% at a 50 µM concentration (Table 2) . In a docked model of 11 ( Figure 5 ), the secondary amine in the extended linker engages in a hydrogen bond with the side chain carboxylate of Glu 63, in a manner similar to that of the secondary amine found in the linker of SMNPI 1 ( Figure 3A) . Furthermore, the extended tether also orients the 3R-oxygen atom of 11 toward the stern layer, eliminating the possibility of unfavorable contacts with polar enzyme residues ( Figure 5 ). However, due to the increased length of the SMNPI, the cholate-acetate portion of 11 cannot attain the same depth of binding as that of 1-3, thus rationalizing its reduced activity (for comparison, 3 inhibits the BoNT/A LC by 90% at 50 µM concentration). Specifically, the extended linker forces the cholate-acetate portion of 11 to adopt a shallower binding mode, with its C23 methoxycarbonyl oriented outside of the substrate binding cleft ( Figure 5 ). In addition, while the SMNPI's 12R-acetyl group faces binding subsite 2, it does so in a sterically shallow location in the substrate cleft that is adjacent to flexible loop 2 ( Figure 5 ). For comparison, the 12R-acetyl substituent of 3 binds in a deeper location in subsite 2 that is directly behind catalytic engine residue His 226 ( Figure 3C ). However, it is noteworthy that the C10 methyl of 11 does adopt a binding site location that occupies the steric space behind Pro 238, as also observed for substituents comprising pharmacophore component G in SMNPIs 1-3.
Based on the examination of substructures 5-9 and derivatives 10 and 11, the importance of pharmacophore component E to the potencies of SMNPIs in this structural class is evident. Indeed, Table 2 shows that each time this pharmacophoric feature is added, the potency of its derivative increases substantially, in one of the most extreme cases, compound 10 versus SMNPI 11, by nearly 7-fold. Additionally, replacement of the aliphatic amine in SMNPI 3 with a polar, non-ionizable oxygen isostere results in an inhibitor that is 10-fold less active. Interestingly, even as pharmacophore component E is key to BoNT/A LC inhibition, it is also central to the hypothesis that these molecules may act as BoNT translocation inhibitors, as the ionizable, aliphatic amine would be responsible for elevating the pH of the toxin-induced endosome. Indeed, we hypothesize that alkalinization of the endosome by the ionizable amine component of the ACQs will potentially result in the trapping and accumulation of these small molecules in the acidic compartment; hence, the in vivo efficacies of the ACQ-based inhibitors may be even more pronounced than anticipated from in vitro studies.
Chemistry. The syntheses of SMNPIs 1-4, and derivatives 10 and 11, have not been reported. Because of the process whereby 1-4 were identified as BoNT/A LC inhibitors, presenting their syntheses at the beginning of the Results and Discussion would not follow the scientific evolution of this study. Therefore, descriptions of the syntheses of the inhibitors and derivatives are provided at a non-traditional, but more logical, location in the text.
Targets 1, 2, 3, and 11 were obtained by amination reactions of corresponding precursors with 6 (Scheme 1). The key aldehyde 15 was obtained from alcohol 13, which was allylated and subsequently ozonized (Scheme 1). Amino ether 11 (43% from 14) was obtained in a reductive amination reaction between 6 and aldehyde 15 (Scheme 1). Alternatively, ketone 19 (obtained from 13) 43 underwent amination with 6 to afford quinoline epimers 2 and 3 (Scheme 1) in a ratio of 1.3:1. Interestingly, although the reactive intermediate is an imine (iminium cation, sp 2 C3), the reductive amination of the cholic acid derivative (5 -series) afforded epimeric 2 and 3 in comparable amounts, unlike the reductions of 5 -3-ketones affording almost exclusively equatorial 3R-epimer. 44 Azide 17, obtained from alcohol 16, was transformed into amine 18 and coupled to 4,7-dichloroquinoline, affording compound 10 (Scheme 1). Finally, quinolines 6 and 7 45 and trisquinoline 4 (33%) were obtained according to a well-established procedure 43 using the corresponding di-and triamines and 4,7-dichloroquinoline.
Conclusion
An expanded/refined pharmacophore for BoNT/A LC inhibition 33 was used to identify four new, potent SMNPIs of the ACQ structural class. In each case, docking of the inhibitors demonstrated that they follow a consistent structure-based theme, engaging in intermolecular substrate binding cleft contacts modeled for other SMNPIs. [31] [32] [33] However, unlike any other BoNT/A LC inhibitors that we have identified to date, 31, 33 SMNPIs 1-4 and 11 incorporate a new pharmacophore component G, which is predicted to serve as a hydrophobic anchor at the edge of the substrate binding cleft, resulting in greater cleft complementarity and occupancy. This provides additional support that molecular scaffolds, which are larger than many reported BoNT/A LC inhibitors, 31, [40] [41] [42] are needed to provide superior inhibition. Finally, examination of substructures composing 1-4 (i.e., compounds 5-9), as well as derivatives 10 and 11, revealed the critical importance of positive-ionizable pharmacophore component E to the potencies of inhibitors in the structural class. This information will be central to the structure-based design of future ACQ-based inhibitors of the BoNT/A LC.
Experimental Section
Chemistry. General Considerations. Melting points were determined on a Boetius PMHK or a Mel-Temp apparatus and were not corrected. Optical rotations were measured on a Rudolph Research Analytical automatic polarimeter, Autopol IV. IR spectra were recorded on a Perkin-Elmer spectrophotometer FT-IR 1725X. NMR spectra were recorded on Varian Gemini-200, Varian XL-300, and Bruker AM-250 spectrometers in the indicated solvent using TMS as internal standard. EI and CI mass spectra were recorded on a MS Finnigan-MAT 8230 spectrometer with double focusing reverse geometry, using isobutane (CI). Figure 3 . As compared to SMNPIs 1-3, the cholate-acetate portion of the inhibitor adopts a shallower binding mode as a result of increasing the length of the flexible tether between the ACQ and cholate-acetate components.
diamine (7), and methyl 3R-amino-7R,12R-diacetoxycholan-24-oate (9) were prepared according to known procedures. [45] [46] [47] [48] [49] Methyl cholate triacetate (8) was purchased form Aldrich and used as obtained.
N-(3r,7r,12r-Triacetoxy-5 -cholan-24-yl)-N′-(7′-chloroquinolin-4′-yl)-ethane-1,2-diamine (1). Methanesulfonyl chloride (84.9 µL, 1.09 mmol) was added to an ice-cold solution of 3R,7R,12R-diacetoxy-5 -cholan-24-ol 50 (12) (Scheme 1) (381.9 mg, 0.73 mmol) in dry pyridine (10 mL), and the resulting mixture was stirred at 0°C for 1 h. Diethyl-ether (30 mL) was added, and the organic layer was washed with diluted HCl (1/1), followed by sat. NaHCO 3 (2 × 15 mL) and brine, and dried over anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure, leaving the crude mesylate (411.7 mg; 94%). In the next step, the crude mesylate and 6 (305.9 mg, 1.38 mmol) were stirred overnight at 60°C in dry DMF (4 mL) and evaporated to dryness. The resulting solid was purified on a SiO 2 column (dry-flesh, AcOEt (8 × 10 mL), AcOEt/MeOH/NH 3 ) 9/1/1 (14 × 10 mL)). Fractions were combined, evaporated to dryness, suspended in CH 2 Cl 2 , and undissolved 6 was removed by filtration. (19) (Scheme 1) (504 mg, 1.0 mmol) and 6 (1.7 g, 7.7 mmol) was dissolved in a CH 3 CN/MeOH (2/1, 15 mL) mixture, and NaBH 3 CN (77.3 mg, 1.23 mmol) was added in one portion. The resulting mixture was stirred for 2 h at room temperature, followed by the addition of glacial AcOH (5 drops). The stirring was continued until TLC indicated the consumption of all starting ketone, ca. 1 h. The solvent was removed under reduced pressure, and the obtained solid was triturated with CH 2 Cl 2 (3 × 40 mL). The dichloromethane extracts were combined, the solvent was removed, and the products were separated by column chromatography (Lobar B Lichroprep RP-18, eluent MeOH/H 2 O ) 9/1) to afford 2 and 3. 2938s, 2875m, 1731s, 1618m, 1594s, 1530m, 1471m, 1451m,  1378s, 1333m, 1250s, 1172m, 1142w, 1108w, 1029m, 961w, 931w , 887w, 853w, 809m, 765w, 730w, 608w, 509w cm -1 . 1 (13)). 13 2870m, 1736s, 1618w, 1589s, 1540w, 1452m, 1378m, 1334w,  1250s, 1200w, 1172w, 1142w, 1084w, 1030m, 971w, 941w, 888w,  853w, 814w, 770w, 647w, 613w, 559w, 509w, 480w, 455w (13)). 13 Tris[3-(7-chloroquinolin-4-yl)aminopropyl]amine (4). Following the procedure of Vennerstrom et al., 43 a solution of 4,7-dichloroquinoline (2.97 g, 15 mmol), triethylamine (1.52 g, 15 mmol), and tris-(3-aminopropyl)amine (0.94 g, 5 mmol) in Nmethylpyrrolidinone (NMP, 10 mL) was subject to 10 purge-cycles using a Firestone valve and then heated to reflux for 7 h under a slight positive N 2 pressure. After the reaction mixture cooled to room temperature, ether (50 mL) and water (50 mL) were added with stirring. After the mixture was cooled in the refrigerator, a tan solid was filtered and washed with water and ethyl acetate to provide, after crystallization from methanol, 4 (1.12 g, 33%). , and phenol (223 mg, 2.32 mmol) was stirred for 24 h at 120°C. Upon cooling, the mixture was dissolved in CH 2 Cl 2 and washed with dilute NaOH (6 × 20 mL) and brine, and dried over anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure, and the product was isolated by column SiO 2 chromatography: dry-flash, 2 × 7 mL hexane, 2 × 7 mL EtOAc: hexane (9:1), 2 × 7 mL EtOAc, 10 × 7 mL EtOAc:MeOH 3531w, 3413w, 2951s,  2870m, 1733s, 1611w, 1581s, 1536w, 1446m, 1376s, 1333w, 1248s,  1200w, 1172w, 1146w, 1101m, 1024m, 967w, 940w, 850w, 810w , 768w, cm (13)). 13 N-(Methyl 7r,12r-diacetoxy-5 -cholan-24-oate,3r-yloxy)-ethyl-N′-(7-chloroquinolin-4-yl)-ethane-1,2-diamine (11) . A sus-
